FindTrial
Sign In

Lucitanib

DRUG9 trials

Sponsors

Institut de Recherches Internationales Servier, Clovis Oncology, Inc., Teresa Helsten, MD, Haihe Biopharma Co., Ltd., pharmaand GmbH

Conditions

Advanced CancerAdvanced Lung CancerAdvanced Solid TumorAdvanced Solid TumorsBreast CancerCarcinoma, Non-small Cell Lung CancerEREstrogen Receptor Positive

Phase 1

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
CompletedNCT01283945
Institut de Recherches Internationales ServierSolid Tumors
Start: 2010-07-31End: 2017-05-04Updated: 2024-07-25
Study of the AL3810 in the Treatment of Advanced Solid Tumor
CompletedNCT03117101
Haihe Biopharma Co., Ltd.Advanced Solid Tumors
Start: 2014-03-31End: 2016-09-30Updated: 2017-04-17
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
TerminatedNCT03992131
pharmaand GmbHOvarian Cancer, Solid Tumor, Triple-negative Breast Cancer +1
Start: 2019-06-28End: 2022-04-22Updated: 2024-01-16
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
SuspendedNCT04042116
Clovis Oncology, Inc.Advanced Solid Tumor, Gynecologic Cancer
Start: 2019-07-29End: 2024-01-31Target: 227Updated: 2022-12-20
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
WithdrawnNCT04151563
Bristol-Myers SquibbCarcinoma, Non-small Cell Lung Cancer
Start: 2021-04-15End: 2026-05-13Updated: 2023-12-19

Phase 2

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
CompletedNCT02053636
Institut de Recherches Internationales ServierBreast Cancer
Start: 2013-12-31End: 2017-04-04Updated: 2024-07-25
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
TerminatedNCT02109016
Clovis Oncology, Inc.Advanced Lung Cancer, Lung Cancer, Metastatic Lung Cancer +6
Start: 2014-04-30End: 2016-09-30Updated: 2019-07-29
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
TerminatedNCT02202746
Clovis Oncology, Inc.Breast Cancer, ER, Estrogen Receptor Positive +5
Start: 2014-09-09End: 2017-01-18Updated: 2020-06-23
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
WithdrawnNCT02747797
Teresa Helsten, MDAdvanced Cancer
Start: 2017-04-30End: 2022-04-30Updated: 2018-08-02

Related Papers

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
Nature Communications2022-12-0822 citations
Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.
2022-07-182 citations
Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
Journal of Clinical Oncology2022-06-012 citations
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
Journal of Clinical Oncology2021-05-204 citations
LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.
Journal of Clinical Oncology2021-05-201 citations
Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
Annals of Oncology2018-10-012 citations
Abstract 784: Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in <i>FGFR3</i> translocated tumor models
Cancer Research2015-08-011 citations
A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
Journal of Clinical Oncology2014-05-2012 citations